Sari Suomela

Sari Suomela

Auto-generated profile, based on publicly available information

Sari Suomela

Finnish Institute of Occupational Health (FIOH), Occupational Medicine Helsinki Finland

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
VFVittorio Fortino
Vittorio Fortino
LWLukas Wisgrill
Lukas Wisgrill
PWPaulina Werner
Paulina Werner
SSSari Suomela
Sari Suomela
NLNina Linder
Nina Linder
NFNanna Fyhrquist
Nanna Fyhrquist
Contact dermatitis tremendously impacts the quality of life of suffering patients. Currently, diagnostic regimes rely on allergy testing, exposure specification, and follow-up visits; however, distinguishing the clinical phenotype of irritant and allergic contact dermatitis remains challenging. Employing integrative transcriptomic analysis and machine-learning approaches, we aimed to decipher disease-related signature genes to find suitable sets of biomarkers. A total of 89 positive patch-test reaction biopsies against four contact allergens and two irritants were analyzed via microarray. Coexpression network analysis and Random Forest classification were used to discover potential biomarkers and selected biomarker models were validated in an independent patient group. Differential gene-expression analysis identified major gene-expression changes depending on the stimulus. Random Forest classification identified CD47, BATF, FASLG, RGS16, SYNPO, SELE, PTPN7, WARS, PRC1, EXO1, RRM2, PBK, RAD54L, KIFC1, SPC25, PKMYT, HISTH1A, TPX2, DLGAP5, TPX2, CH25H, and IL37 as potential biomarkers to distinguish allergic and irritant contact dermatitis in human skin. Validation experiments and prediction performances on external testing datasets demonstrated potential applicability of the identified biomarker models in the clinic. Capitalizing on this knowledge, novel diagnostic tools can be developed to guide clinical diagnosis of contact allergies. Significance Contact dermatitis is an inflammatory skin disorder that arises from direct skin contact with irritants or allergens. Representing over 90% of occupational skin disorders, it has a considerable socioeconomic impact, and patients suffering from contact dermatitis can develop a notable physical handicap. Current diagnostic regimes rely on allergy testing, exposure specification, and follow-up visits. However, distinguishing the clinical phenotype of irritant and allergic contact dermatitis, which is important for appropriate therapeutic strategies, remains challenging. This study identifies and validates biomarkers to distinguish allergic and irritant contact dermatitis in human skin, to be used for the development of novel diagnostic methods and to guide clinical diagnosis.

19 September 2018 in Contact Dermatitis
Verified
Journal Article
Closed access
PDF file
MPMaria Pesonen
Maria Pesonen
KSKatri Suuronen
Katri Suuronen
SSSari Suomela
Sari Suomela
KAKristiina Aalto‐Korte
Kristiina Aalto‐Korte

4 June 2018 in BMC Genomics
Verified
Journal Article
Open access
PDF file
MTMari H. Tervaniemi
Mari H. Tervaniemi
SKShintaro Katayama
Shintaro Katayama
TSTiina Skoog
Tiina Skoog
HSH. Annika Siitonen
H. Annika Siitonen
Jyrki VuolaJyrki Vuola
Jyrki Vuola
OEOuti Elomaa
Outi Elomaa
CCHCR1 (Coiled-Coil α-Helical Rod protein 1) is a putative psoriasis candidate gene with the risk alleles CCHCR1*WWCC and *Iso3, the latter inhibiting the translation of isoform 1. CCHCR1 was recently shown to be a centrosomal protein, as well as a component of cytoplasmic processing bodies (P-bodies) that regulate mRNA turnover. The function of CCHCR1 has remained unsettled, partly because of the inconsistent findings; it has been shown to play a wide variety of roles in divergent processes, e.g., cell proliferation and steroidogenesis. Here we utilized RNA sequencing (RNAseq) using HEK293 cells overexpressing isoforms 1 or 3 (Iso1, Iso3 cells), in combination with the coding non-risk or risk (*WWCC) haplotype of CCHCR1. Our aim was to study the overall role of CCHCR1 and the effects of its variants. The overexpression of CCHCR1 variants in HEK293 cells resulted in cell line-specific expression profiles though several similarities were observable. Overall the Iso1 and Iso3 cells showed a clear isoform-specific clustering as two separate groups, and the Non-risk and Risk cells often exhibited opposite effects. The RNAseq supported a role for CCHCR1 in the centrosomes and P-bodies; the most highlighted pathways included regulation of cytoskeleton, adherens and tight junctions, mRNA surveillance and RNA transport. Interestingly, both the RNAseq and immunofluorescent localization revealed variant-specific differences for CCHCR1 within the P-bodies. CCHCR1 influenced a wide variety of signaling pathways, which could reflect its active role in the P-bodies and centrosomes that both are linked to the cytoskeleton; as a centrosomal P-body protein CCHCR1 may regulate diverse cytoskeleton-mediated functions, such as cell adhesion and -division. The present findings may explain the previous inconsistent observations about the functions of CCHCR1.

29 May 2024 in Contact Dermatitis
Verified
Journal Article
Open access
SMSwen Malte
Swen Malte
ABAndreas Bonertz
Andreas Bonertz
JZJulia Zimmer
Julia Zimmer
OAOlivier Aerts
Olivier Aerts
ABAndrea Bauer
Andrea Bauer
JJJeanne Duus Johansen
Jeanne Duus Johansen
Patch testing is the only clinically applicable diagnostic method for Type IV allergy. The availability of Type IV patch test (PT) allergens in Europe, however, is currently scarce. This severely compromises adequate diagnostics of contact allergy, leading to serious consequences for the affected patients. Against this background, the European Society of Contact Dermatitis (ESCD) has created a task force (TF) (i) to explore the current availability of PT substances in different member states, (ii) to highlight some of the unique characteristics of Type IV vs. other allergens and (iii) to suggest ways forward to promote and ensure availability of high‐quality patch testing substances for the diagnosis of Type IV allergies throughout Europe. The suggestions of the TF on how to improve the availability of PT allergens are supported by the ESCD, the European Academy of Allergy and Clinical Immunology, and the European Academy of Dermatology and Venereology and intend to provide potential means to resolve the present medical crisis.

19 April 2022 in Contact Dermatitis
Verified
Journal Article
Open access
SSSari Suomela
Sari Suomela
MPMaria Pesonen
Maria Pesonen
KYKatriina Ylinen
Katriina Ylinen
KAKristiina Aalto‐Korte
Kristiina Aalto‐Korte
KSKatri Suuronen
Katri Suuronen
Background: The practical importance of two recently described epoxy hardener allergens—1,3‐benzenedimethanamine, N‐(2‐phenylethyl) derivatives (1,3‐BDMA‐D) and hydrogenated formaldehyde benzenamine polymer (FBAP)—as occupational allergens remains to be defined.Objectives: To describe patients diagnosed at the Finnish Institute of Occupational Health (FIOH) with positive reactions to 1,3‐BDMA‐D or FBAP.Methods: We searched FIOH's patch‐test files from January 2017 to December 2020 for patients examined due to suspected occupational contact allergy to epoxy compounds. We analyzed the patch‐test results and sources of exposure to various epoxy hardeners and focused on occupations, symptoms, and the sources of exposure to 1,3‐BDMA‐D and FBAP.Results: During the study period, 102 patients were examined at FIOH for suspected occupational contact allergy to epoxy compounds. Of these, 19 (19%) were diagnosed with contact allergy to 1,3‐BDMA‐D (n = 10) or FBAP (n = 12). The largest occupational group was sewage pipe reliners (n = 8). Seven different hardener products contained FBAP, whereas 1,3‐BDMA‐D was present in only one hardener used by spray painters.Conclusions: A substantial number of patients with suspected occupational epoxy resin system allergy tested positive to in‐house test substances of 1,3‐BDMA‐D and/or FBAP.

24 October 2017 in Contact Dermatitis
Verified
Journal Article
Closed access
PDF file
SSSari Suomela
Sari Suomela
KMKari Mölsä
Kari Mölsä
KAKristiina Aalto‐Korte
Kristiina Aalto‐Korte
KSKatri Suuronen
Katri Suuronen